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In response  to antimicrobial  resistance  of  Neisseria  gonorrhoeae  to  last-resort  extended-spectrum
cephalosporins,  combination  therapy  of azithromycin  + ceftriaxone  is  now  recommended.  Dual ther-
apy can  be effective  to treat  monoresistant  strains  as  well  as  multidrug-resistant  strains,  preferably
employing  the  effect  of  in vitro  synergy.  As reports  on  in vitro  synergy  of  azithromycin  + ceftriaxone
in  N. gonorrhoeae  are  conﬂicting,  in this  study  an  evaluation  of this  combination  was  performed  using
a  cross-wise  Etest  method  and agar  dilution.  Synergy  was  deﬁned  as  a fractional  inhibitory  concen-
tration  index  (FICI)  of ≤0.5.  To  identify  other  dual  treatment  options  for gonorrhoea,  in vitro  synergy
was  evaluated  for 65  dual antimicrobial  combinations  using  Etest.  Azithromycin,  ceﬁxime,  ceftriaxone,
colistin,  ertapenem,  fosfomycin,  gentamicin,  minocycline,  moxiﬂoxacin,  rifampicin,  spectinomycin  and
tigecycline were  screened  for synergy  in  all  possible  combinations.  No  synergy  or  antagonism  was  found
for any  of the  65  combinations.  The  geometric  mean  FICI  ranged  from  0.82  to 2.00.  The  mean  FICI  of
azithromycin  + ceftriaxone  was  1.18 (Etest)  and  0.55 (agar  dilution).  The  difference  between  both  meth-
ods  did  not  result  in  a difference  in  interpretation  of synergy.  Ceftriaxone-resistant  strain  F89 was  tested
in all  combinations  and  no  synergy  was  found  for  any  of  them.  Most  importantly,  the  ceftriaxone  min-
imum  inhibitory  concentration  of  F89  was  not  decreased  below  the  breakpoint  with  any  concentration
of  azithromycin.
lsevie© 2014  E
. Introduction
Gonorrhoea is the most prevalent bacterial sexually transmit-
ed infection worldwide [1]. If left untreated it can cause severe
llness such as pelvic inﬂammatory disease or infertility and it
ncreases the transmission of human immunodeﬁciency virus
HIV). However, the causative bacterium Neisseria gonorrhoeae has
ow become resistant to the last-resort monotherapy of extended-
pectrum cephalosporins [2]. With few new antimicrobial drugs in
he pipeline, this renders gonorrhoea potentially untreatable in the
uture.
Therefore, the US Centers for Disease Control and Prevention
CDC) as well as UK and European treatment guidelines now
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etherlands. Tel.: +31 20 555 5293; fax: +31 20 555 5533.
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recommend dual therapy of azithromycin and ceftriaxone [3–5].
Dual therapy can be effective even if the organism is resistant to
one of the drugs, and in addition it can relieve the selection pres-
sure on an organism to become resistant. Combination therapy with
azithromycin has the advantage to treat possible co-infection with
Chlamydia trachomatis. Another reason for dual therapy is synergy,
where the combined effect of two  drugs is greater than the mere
sum of the effects of both drugs alone [6].
In vitro synergy has been demonstrated with different antimi-
crobials in various Gram-negative bacteria [7,8]. In N. gonorrhoeae,
this has been described for azithromycin + ceﬁxime [9]. However,
more recently Pereira et al. and Barbee et al. did not ﬁnd syn-
ergy for azithromycin + ceﬁxime or ceftriaxone [10,11]. If synergy
in N. gonorrhoeae can be demonstrated, multidrug-resistant strains
could be treated with earlier empirically proven effective treat-
ment options. Therefore, the aim of this study was  to determine
in vitro synergy in N. gonorrhoeae for azithromycin + ceftriaxone
as well as to evaluate synergy in other possible dual antimicrobial
combinations.
 reserved.
3 l of An
2
2
2
e
(
f
a
d
S
2
v
(
t
i
t
O
N
p
i
b
o
b
A
c
(
o
w
2
2
b
a
f
s
c
(
t
i
I
c
n
h
s
a
t
w
t
2
w
a
F
a
f06 C.M. Wind et al. / International Journa
. Materials and methods
.1. Synergy testing for azithromycin + ceftriaxone
.1.1. Bacterial isolates
This study included 12 clinical N. gonorrhoeae isolates, refer-
nce strains WHO  K and L and ceftriaxone-resistant strain F89
isolated in France in 2010) [2,12]. These 15 isolates were selected
or their highest minimum inhibitory concentration (MIC) of both
zithromycin (0.047–8.0 mg/L) and ceftriaxone (0.008–1.0 mg/L)
etermined by Etest as described by the manufacturer (bioMérieux
A, Marcy-l’Étoile, France).
.1.2. Synergy testing, deﬁnition and interpretation
To determine synergy for azithromycin + ceftriaxone, two  pre-
iously described methods were used, one using double Etests
positioned cross-wise at a 90◦ angle) and one using agar dilu-
ion [13–15]. In the latter method, azithromycin (0.032–32 mg/L
n 11 two-fold dilutions) and ceftriaxone (0.008–4.0 mg/L in 10
wo-fold dilutions) were added to GC agar (prepared in-house at
nze Lieve Vrouwe Gasthuis General Hospital, Amsterdam, The
etherlands). Then, 10 L of 0.5 McFarland standard prepared in
hosphate-buffered saline each of 15 N. gonorrhoeae isolates was
noculated onto the GC agar plates (120 × 120 mm).
With either method, MICs were determined for both antimicro-
ials alone (MICAalone and MICBalone) and in combination with the
ther (MICAcombi and MICBcombi). MICs were read following incu-
ation at 37 ◦C in 5% CO2 for 16–18 h (Etest) or 24 h (agar dilution).
ll experiments were performed in duplicate.
The fractional inhibitory concentration index (FICI) was  cal-
ulated using the following formula: FICI = (MICAcombi/MICAalone) +
MICBcombi/MICBalone). A FICI of ≤0.5 was deﬁned as synergy, a FICI
f >0.5 but ≤4.0 was deﬁned as no interaction, and a FICI of >4.0
as deﬁned as antagonism [6].
.2. Synergy testing for 65 antimicrobial dual combinations
.2.1. Antimicrobial combinations
Based on in vitro synergy described in other Gram-negative
acteria, 12 antimicrobial agents were selected, namely
zithromycin, ceﬁxime, ceftriaxone, colistin, ertapenem, fos-
omycin, gentamicin, minocycline, moxiﬂoxacin, rifampicin,
pectinomycin and tigecycline [7–9]. With the exception of
eﬁxime + ceftriaxone, all possible dual combinations were tested
n = 65).
First, these 65 combinations were screened for synergy using
he double Etest method [13]. This screening was performed on four
solates per combination and was used as a crude selection method.
f the FICI was <1.0 in at least 3 of the 4 tested isolates for a speciﬁc
ombination, that combination was re-tested using 11 isolates.
Combinations with ceﬁxime were selected over combi-
ations with ceftriaxone, as oral administration of ceﬁxime
as practical advantages, especially in general practitioner
ettings. Azithromycin + ceﬁxime was included in any case;
zithromycin + ceftriaxone was already tested as described in Sec-
ion 2.1. All experiments were performed in duplicate. If synergy
as inconsistent between both experiments, it was performed a
hird time.
.2.2. Bacterial isolates
For each antimicrobial combination, four N. gonorrhoeae isolates
ere selected from a panel consisting of WHO  strains K, L, M,  O, P
nd G, control strain ATCC 49226, strain F89 and 24 clinical isolates.
or each combination, ceftriaxone-resistant strain F89 was  selected
nd the other three isolates were selected based on the highest MICs
or that speciﬁc combination.timicrobial Agents 45 (2015) 305–308
The panel of 11 isolates used for re-testing was  identical for all
combinations and included WHO  strains K and L, strain F89 and 8
of the clinical isolates described in Section 2.1.1.
2.3. Statistical analysis
MICs and FICIs were calculated as geometric means of all isolates
and duplicate experiments in each antimicrobial combination. The
difference in FICI between Etest and agar dilution was deﬁned using
a Wilcoxon signed-rank test. A P-value of <0.05 was considered sta-
tistically signiﬁcant. Analyses were performed using SPSS Statistics
for Windows v.21.0 (IBM Corp., Armonk, NY).
3. Results
3.1. Synergy of azithromycin + ceftriaxone
When testing azithromycin + ceftriaxone using Etest, the geo-
metric mean MIC  decreased for azithromycin from 0.27 mg/L to
0.15 mg/L and for ceftriaxone from 0.062 mg/L to 0.037 mg/L. The
mean FICI of all isolates was 1.18 (range 0.58–2.00), indicating no
interaction. No individual isolates showed a FICI ≤ 0.5.
When using agar dilution, the mean MIC  (range) decreased
for azithromycin from 0.56 mg/L (0.125–16.0 mg/L) to
0.092 mg/L (0.032–0.5 mg/L) and for ceftriaxone from 0.082 mg/L
(0.016–2.0 mg/L) to 0.025 mg/L (0.008–1.0 mg/L). The mean FICI
was 0.55 (range 0.16–0.76), indicating no interaction. Four of the
15 individual isolates showed a FICI ≤ 0.5: three isolates with a FICI
between 0.44 and 0.50, and one isolate with a FICI of 0.16.
When comparing the mean FICI of the Etest and agar dilution
methods, a signiﬁcant difference (P = 0.001) was  found, with agar
dilution resulting in lower FICIs than the Etest method.
3.2. Synergy of 65 dual antimicrobial combinations
Results of the screening of 65 dual combinations showed
no synergy for any combination; the mean FICI ranged from
0.82 to 2.00 (Table 1). Five combinations showed a FICI < 1.0
in three of the four tested isolates: ceﬁxime + ertapenem;
ceﬁxime + gentamicin; ceﬁxime + moxiﬂoxacin; ceftriaxone +
ertapenem; and ertapenem + fosfomycin.
When these combinations, plus azithromycin + ceﬁxime
and azithromycin + ceftriaxone, but without ceftriaxone +
ertapenem, were tested on 11 isolates, mean FICIs were:
azithromycin + ceﬁxime, 0.83; ceﬁxime + ertapenem, 0.77;
ceﬁxime + gentamicin, 0.97; ceﬁxime + moxiﬂoxacin, 1.13; and
ertapenem + fosfomycin, 0.86; all indicating no interaction
(Table 2).
3.3. Synergy in ceftriaxone-resistant strain F89
Ceftriaxone-resistant strain F89 was used in all experi-
ments in this study. None of the 65 combinations tested
showed synergy with this isolate. When using Etest for the
combinations as described in Table 2, this resulted in the
following mean MICs of antimicrobials alone: azithromycin,
0.22 mg/L; ceﬁxime, 1.73 mg/L; ceftriaxone, 0.87 mg/L; ertapenem,
0.004 mg/L; fosfomycin, 16.0 mg/L; gentamicin, 2.0 mg/L; and mox-
iﬂoxacin, 1.50 mg/L. The mean FICIs were: azithromycin + ceﬁxime,
1.00; azithromycin + ceftriaxone, 1.20; ceﬁxime + ertapenem, 0.69;
ceﬁxime + gentamicin, 1.46; ceﬁxime + moxiﬂoxacin, 1.37; and
ertapenem + fosfomycin, 0.69; all indicating no interaction.Testing of azithromycin + ceftriaxone using agar dilution
resulted in a mean MIC  alone of 0.5 mg/L and 2.0 mg/L, respectively,
and a FICI of 0.56, indicating no synergy. Adding azithromycin in any
dosage did not decrease the ceftriaxone MIC  for strain F89 below
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Table  1
Results of in vitro synergy experiments of 65 antimicrobial combinations in four Neisseria gonorrhoeae isolates using the Etest method.
Antimicrobial
A
Geometric mean FICIa (no. of strains with FICI < 1.0)
Antimicrobial B
Ceﬁxime Ceftriaxone Colistin Ertapenem Fosfomycin Gentamicin Minocycline Moxiﬂoxacin Rifampicin Spectinomycin Tigecycline
Azithromycin 0.93 (2) 1.59 (1) 1.54 (1) 1.42 (0) 1.75 (0) 1.75 (0) 1.17 (1) 1.31 (1) 1.51 (0) 1.55 (1) 1.29 (0)
Ceﬁxime –b 1.04 (2) 0.82 (3) 1.02 (1) 0.87 (3) 1.10 (0) 0.93 (3) 1.44 (0) 1.04 (1) 1.10 (1)
Ceftriaxone 1.23 (1) 0.91 (3) 1.01 (2) 1.30 (1) 1.58 (0) 1.47 (0) 1.78 (0) 1.33 (0) 2.00 (0)
Colistin 0.98 (2) 1.10 (0) 1.27 (0) 1.08 (2) 1.07 (1) 1.45 (0) 1.65 (0) 1.09 (1)
Ertapenem 0.90 (3) 1.18 (1) 1.66 (0) 0.96 (2) 1.70 (0) 1.48 (0) 1.50 (0)
Fosfomycin 1.29 (1) 1.58 (0) 1.35 (0) 1.38 (1) 1.28 (1) 1.80 (0)
Gentamicin 1.06 (0) 1.20 (0) 1.49 (0) 1.60 (0) 1.37 (1)
Minocycline 1.20 (1) 1.19 (1) 1.37 (0) 1.08 (2)
Moxiﬂoxacin 1.54 (0) 1.28 (0) 1.08 (0)
Rifampicin 1.62 (0) 1.53 (1)
Spectinomycin 1.21 (1)
FICI, fractional inhibitory concentration index.
a Geometric mean FICI of four varying N. gonorrhoeae isolates per combination, each combination containing ceftriaxone-resistant strain F89.
b Combination was  not tested.
Table 2
Geometric mean MIC  and FICI of six antimicrobial combinations against 11 Neisseria gonorrhoeae isolates using the Etest method.
Antimicrobial combination Mean MIC  (range) (mg/L) Mean FICI (range)
Azithromycin Ceﬁxime
Alone Combination Alone Combination
Azithromycin + ceﬁxime 0.26 (0.094–8.0) 0.106 (0.023–3.0) 0.11 (0.016–2.0) 0.047 (0.012–1.0) 0.83 (0.49–1.41)
Azithromycin Ceftriaxone
Alone Combination Alone Combination
Azithromycin + ceftriaxonea 0.27 (0.047–8.0) 0.153 (0.016–4.0) 0.062 (0.008–1.0) 0.037 (0.004–0.75) 1.18 (0.58–2.0)
Ceﬁxime Ertapenem
Alone Combination Alone Combination
Ceﬁxime + ertapenem 0.11 (0.016–2.0) 0.047 (0.012–0.75) 0.036 (0.004–0.125) 0.013 (0.001–0.064) 0.77 (0.49–1.27)
Ceﬁxime Gentamicin
Alone Combination Alone Combination
Ceﬁxime + gentamicin 0.11 (0.016–2.0) 0.052 (0.016–1.5) 1.98 (0.75–3.0) 0.99 (0.5–2.0) 0.97 (0.51–2.0)
Ceﬁxime Moxiﬂoxacin
Alone Combination Alone Combination
Ceﬁxime + moxiﬂoxacin 0.11 (0.016–2.0) 0.065 (0.012–1.5) 2.33 (1.0–6.0) 1.28 (0.75–3.0) 1.13 (0.66–1.43)
Ertapenem Fosfomycin
Alone Combination Alone Combination
Ertapenem + fosfomycin 0.036 (0.004–0.125) 0.014 (0.001–0.064) 13.3 (8.0–48) 6.19 (2.0–24) 0.86 (0.51–1.45)
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a For this combination, 15 N. gonorrhoeae isolates were used.
.0 mg/L. The azithromycin MIC  only decreased after adding cef-
riaxone in concentrations of ≥1.0 mg/L, which was only 1 dilution
elow the MIC  for ceftriaxone alone.
. Discussion
In this study, a lack of in vitro synergy was demonstrated
or any of 65 dual antimicrobial combinations against N. gonor-
hoeae.  Moreover, no synergy was observed in ceftriaxone-resistant
train F89 with any of the tested antimicrobial combinations.
he results of this study do not support the results of Furuya
t al., who reported synergy for azithromycin + ceﬁxime [9]. The
ack of synergy found in novel combinations of a third-generation
ephalosporin with gentamicin, rifampicin or fosfomycin supports
ecent ﬁndings by Barbee et al. [11]. The present results sug-
est that of the antimicrobial combinations using azithromycin,
eﬁxime, ceftriaxone, colistin, ertapenem, fosfomycin, gentamicin,
inocycline, moxiﬂoxacin, rifampicin, spectinomycin and tigecy-
line, none are promising candidates for gonorrhoea dual therapy,
f such therapy was based only on in vitro synergy. However, no
ntagonism was found for any of these combinations, indicating no
bjections to clinical studies of these combinations as dual therapy
or gonorrhoea.
In addition to the lack of synergy with novel combinations,
o synergy was also found for the recommended dual therapyof azithromycin + ceftriaxone using either Etest or agar dilution.
Only when using agar dilution were FICIs of ≤0.5 found in four
individual isolates; one was 0.16 and the other three were ≥0.44.
However, this could be due to chance, and given the lack of
synergy in the majority of isolates as well as the results of exper-
iments using Etest, we  consider the results of these individual
isolates not convincing evidence for synergy. Overall, the cur-
rent results support recent ﬁndings by Pereira et al. and Barbee
et al. that no synergy for this combination can be demonstrated
[10,11].
Measuring synergy has several challenges. First, evaluation of
in vitro synergy depends on the method used. Different methods
exist for using double Etests, yet it remains unclear which yields the
most reliable results [7,8,11,13]. When using agar dilution, repro-
ducibility can be a problem, something we however did not see in
the current experiments [6].
Second, variation exists in how to calculate and interpret syn-
ergy. We  used the most widely described FICI. This method was
also used by other studies on synergy in N. gonorrhoeae, allow-
ing comparison of results [9–11]. To avoid suggestive effects for
FICIs of >0.5 and ≤1.0, we chose to deﬁne synergy more strictly, so
all combinations within this range were deﬁned as ‘no interaction’
[6].
There are some limitations to the current study. When testing
the 65 dual combinations, isolates were selected based on highest
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ICs for both antimicrobials, which resulted in a small panel of iso-
ates. Whilst this experiment was conducted as a mere screening
or synergy, this could have led to insufﬁcient power to detect
ynergy. However, no synergy was found when re-testing combi-
ations with FICIs <1.0 using more isolates. Ideal would be a larger
anel with isolates showing high-level resistance to both drugs in
 combination. However, only a few strains with overt resistance
o ceftriaxone have been described so far, and no strains highly
esistant to both azithromycin and ceftriaxone have been isolated.
Both Etest and agar dilution were used to test
zithromycin + ceftriaxone. As in previous studies, a signiﬁ-
ant difference was found when comparing FICIs of both methods
7,8,11]. The most likely explanation for the higher FICIs when
sing Etest is the fact that lateral diffusion gradients of this
ethod are not taken into account. Due to this gradient effect, the
oncentration of antimicrobial A can be lower than the MIC  level
t the location where MICBcombi is read, leading to an overestimate
f MICBcombi and possibly an overestimate of the FICI. In addition,
y using Etest intermediate MICs can also be determined, whilst
n agar dilution only full two-fold dilutions are used. However,
he difference between methods did not lead to a difference in
nterpretation of synergy.
In conclusion, no synergy was found for 65 dual antimicrobial
ombinations as well as no synergy for azithromycin + ceftriaxone,
uggesting that for these combinations synergy might not play a
igniﬁcant role in the treatment of gonorrhoea. Therefore, research
imed at new treatment options against emerging resistant strains
hould move in other directions. One alternative could be to focus
ore on the clinical outcome of dual therapy, given that in vitro
ynergy is subject to uncertain testing methods and does not always
orrespond to a clinical effect, whilst dual therapy could be help-
ul to treat isolates resistant to one of the two antimicrobials and
ossibly decrease selection pressure. In addition, new treatment
ptions are urgently needed and should be tested for the elimina-
ion of N. gonorrhoeae both in vitro and in clinical trials to sustain
he treatment of gonorrhoea in the future.
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